DDInter302 DDInter1676
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Carmustine {u} (Compound) treats {v} (Disease) melanoma
Carmustine {u} (Compound) binds {v} (Gene) CYP1A2
Carmustine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Carmustine {u} (Compound) causes {v} (Side Effect) Vision blurred
Carmustine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Carmustine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Carmustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Carmustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Filgrastim
Carmustine {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Carmustine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Carmustine (Compound) treats melanoma (Disease)
Carmustine (Compound) binds CYP1A2 (Gene)
Carmustine (Compound) is included by Alkylating Activity (Pharmacologic Class)
Carmustine (Compound) causes Vision blurred (Side Effect)
Carmustine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Carmustine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Carmustine may lead to a major life threatening interaction when taken with Rotavirus vaccine
Carmustine may lead to a major life threatening interaction when taken with Cladribine